# Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV

> **NCT04540627** · PHASE1 · COMPLETED · sponsor: **mAbxience Research S.L.** · enrollment: 56 (actual)

## Conditions studied

- Healthy Adult Participants

## Interventions

- **DRUG:** Palivizumab
- **DRUG:** Placebo
- **OTHER:** RSV-A Memphis 37b virus

## Key facts

- **NCT ID:** NCT04540627
- **Lead sponsor:** mAbxience Research S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-06
- **Primary completion:** 2020-10-23
- **Final completion:** 2020-10-23
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2021-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540627, "Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04540627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*